<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01423305</url>
  </required_header>
  <id_info>
    <org_study_id>3103008</org_study_id>
    <nct_id>NCT01423305</nct_id>
  </id_info>
  <brief_title>Phase I Pharmacokinetic Study (BF-BLOCK)</brief_title>
  <acronym>BF-BLOCK</acronym>
  <official_title>Effect of Charcoal on Gastrointestinal Absorption of Budesonide and Formoterol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess if charcoal prevents the absorption of budesonide and
      formoterol via GI track. The assessment will be based on comparing the pharmacokinetic
      parameter area under the concentration-time curve.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The evaluation of primary pharmacokinetic variable AUCt</measure>
    <time_frame>4 weeks</time_frame>
    <description>The evaluation of primary pharmacokinetic variable AUCt of this study will be based on statistical methods appropriate for crossover design.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic variables</measure>
    <time_frame>4 weeks</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic variable</measure>
    <time_frame>4 weeks</time_frame>
    <description>tmax</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide/formoterol capsule (Orion Pharma) for oral administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide/formoterol capsule (Orion Pharma) for oral administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide/formoterol capsule.</intervention_name>
    <description>Oral administration with concomitant charcoal.</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide/formoterol capsule for oral adm.</intervention_name>
    <description>Oral administration without concomitant charcoal.</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males and females aged 18-60 years.

          2. Normal weight at least 50 kg.

        Exclusion Criteria:

          1. Evidence of a clinically significant cardiovascular, renal, hepatic, haematological,
             gastrointestinal, pulmonary, metabolic-endocrine, neurological or psychiatric disease.

          2. Any clinically significant abnormal laboratory value or physical finding that may
             interfere with the interpretation of study results or constitute a health risk for the
             subject if he/she takes part in the study.

          3. Any condition requiring concomitant treatment (including vitamins and herbal products)
             or likely to need any concomitant treatment during the study.

          4. Known hypersensitivity to the active substance(s) or the excipients of the drug.

          5. Pregnant or lactating females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mika Scheinin, M.D.Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Services Turku Finland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Reseach Services Turku (CRST)</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2011</study_first_submitted>
  <study_first_submitted_qc>August 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2011</study_first_posted>
  <last_update_submitted>October 20, 2011</last_update_submitted>
  <last_update_submitted_qc>October 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
    <mesh_term>Charcoal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

